P.5.b. Dementia and neurological disorders − Dementia (clinical) S643 P.5.b.006 Some pharmacological treatment options of psychiatric comorbidity in elderly patients with neurocognitive disorders M. Arnaoudova 1° , A. Tsvetkova 2 , A. Todorova 3 1 Medical University, Dept of psychiatry and medical psychology, Varna, Bulgaria; 2 Medical University, Medical College, Varna, Bulgaria; 3 Medical University, Faculty of Pharmacy, Varna, Bulgaria Background: A wide variety of psychic and behavioral distur- bances in Neurocognitive disorders (NCD’s) are challenging to manage. This might lead to excessive use of psychotropic drugs with risk/benefit issues [1−3]. Aim: To investigate whether psychotropic drugs are accept- able treatment for psychiatric comorbidity in dementia. We also searched for somatic comorbidity and medications received [4]. As the term dementia is more familiar, we would like to use this term in our abstract. Method: We examined 216 in-patients (mean age 73.18) with Alzheimer’s dementia (AD) and Vascular dementia (VaD), who were under psychotropic treatment because of psychiatric comor- bidity. There is a particularly strong association between the two disorders, as well as vascular risk factors [5]. All the patients un- derwent clinical psychiatric assessment, physical examination and evaluation on MMSE, NPI, Cohen-Mansfield Inventory. Descrip- tive statistics and t-test for comparing the means were applied. Analyses were done using Excel 2007. Summary of results: There were no significant differences between the two groups in relation to age and sex. Psychotic states prevailed with some clinical differences. In VaD hallucinations were mostly present, in AD − paranoid delusions dominated. Non- aggressive physically and verbally behaviour disturbances were present in AD patients, aggressive types prevailed in VaD. Treatment decision was based mainly on neuropsychiatric symptoms, secondly-on the very psychiatric disorder. The psy- chotropics included: antipsychotics, benzodiazepines, mood sta- bilizers, cognitive enhancers (Donepezil hydrochloride and Me- mantine). Users of conventional antipsychotics were 36.36% VaD patients and 34.28% AD patients and of atypical antipsychotics 60% of AD and 53% of VaD patients. No serious complications were observed in the two groups. The prevailing aggressive behavioural disturbances in VaD were consistent in preference of mood stabilizers (15.32%) and benzodiazepines (55.86%), than in AD (respectively 6.67% and 37.14%) p < 0.05. We found statistically significant difference between prescrip- tions of Donepezil hydrochloride (26.67%) in AD and 5.41% in VaD (p = 7.35×10 −7 <0.05) and in use of Memantine (31.43%) in AD, respectively 5.41% in VaD (p=7.53×10 −7 <0.05). Somatic comorbidity comprised high blood pressure, ischemic heart disease, diabetes, congestive heart failure, myocardial in- farction. The individuals with VaD had a significantly higher number of chronic conditions (mean = 1.88) than those with AD (mean = 0.96) p = 1.2×10 −10 <0.05. The average number of medications applied for somatic comorbidity in VaD was significantly higher (mean = 2.51) than in AD patients (mean = 1.61) p = 4.9×10 −8 <0.05. The cross-sectional design of our study does not allow for def- inite distinctions among the identified associations. Nevertheless, it generates some proposals, solutions and puts an accent on the clinical complexity of dementia. Psychotropic drugs may be used with caution, given their specific side effect profile for a short-term treatment. The risk of complications with antipsychotics is mainly dose related or could be due to a faster titration. The role of cognitive enhancers in combined treatment or as an alternative in some target groups should be considered. Conclusion: While in the years of introduction of newer psy- chotropic medicaments we looked mainly for efficacy, in the last years we put the accent on safety. A comprehensive medical work-up and close monitoring are prerequisites for a favourable treatment and outcome. References [1] Ballard, C., Corbett, A., 2010. Management of neuropsychiatric symp- toms in people with dementia. CNS Drugs 24(9), 729–739. [2] Rosenberg, P.B., Mielke, M.M., Han, D., Leoutsakos, J.S., Lyketsos, C.G. et al., 2012. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer’s disease. Int J Geriatr Psychiatry 27(12), 1248–1257. [3] Maust, D.T., Kim, H.M., Seyfried, L.S., Chiang, C., Kavanagh, J., et al., 2015. Antipsychotics, Other Psychotropics, and the Risk of Death in Patients With Dementia Number Needed to Harm. JAMA Psychiatry 72(5), 438–445. [4] Poblador-Plou, B., Calder´ on-Larra˜ naga, A., Marta-Moreno, J., Hancco- Saavedra, J., Sicras-Mainar, A., Soljak, M., Prados-Torres, A., 2014. Comorbidity of dementia: a cross-sectional study of primary care older patients. BMC Psychiatry 14, 84. [5] Duthie, A., Chew, D., Soiza, R.L., 2011. Non-psychiatric comorbidity associated with Alzheimer’s disease. QJM 104, 913–920. P.5.b.007 Is apathy in demented elderly correlated with vascular risk factors? E. Cobanoglu 1 , E.T. Ozel-Kizil 1° , B. Bilgin-Kapucu 1 , S. Kirici 1 , D. Oztuna 2 1 Ankara University School of Medicine, Psychiatry, Ankara, Turkey; 2 Ankara University School of Medicine, Biostatistics, Ankara, Turkey Introduction: Apathy is a prevalent neuropsychiatric syndrome that is seen both in early and late stages of dementia [1] and associated with greater cognitive decline, functional impairment, caregiver distress, poorer treatment response and prognosis [2]. It is therefore important to evaluate controllable factors that play a role in the pathogenesis of apathy. Vascular risk factors such as hypertension, diabetes mellitus, high body mass index (BMI), high C-reactive protein levels, history of transient ischemic attack were found to be correlated with apathy levels in demented and non- demented elderly. Hyperlipidemia, hyperhomocysteinemia, coro- nary heart disease, smoking and alcohol consumption were also suggested as risk factors of apathy [3]. The aim of this study is to compare apathy levels in dementia patients with and without vascular risk factors. Methods: A total of 103 elderly outpatients, with ma- jor neurocognitive disorder (NCD) due to Alzheimer’s disease (AD)(n = 76) or both AD and vascular etiology (n = 27) (according to DSM-5 criteria) were recruited to the study. Apathy levels were assessed with Apathy Evaluation Scale − Clinician version (AES-C). Vascular risk factors were investigated via detailed history taking and evaluation of medical records. Apathy levels of patients with and without vascular factors were compared by using Mann–Whitney U test. Results: The mean age of the sample was 77.03±5.88. 43.7% (n = 45) of the patients were female and 56.3% (n = 58) were male. Mean years of education were 6.77±3.97. There was no